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Clinical utility of gene expression levels of ribonucleotide reductase 
subunit M1 (RRM1), tyrosyl-DNA phosphodiesterase (Tdp1), 
nuclear factor of activated T cells (NFAT) and BubR1 mRNA 
expression in completely resected chemonaive non-small-cell lung 
cancer (NSCLC) patients (p)
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Background: There is still a sore need for better characterization of 
factors inﬂuencing survival in speciﬁc subgroups and in individual 
patients with NSCLC. RRM1 is involved in DNA repair, Tdp1 is impli-
cated in the repair of CPT-induced topoisomerase damage, and NFAT 
promotes cancer invasion. BubR1 is a key spindle checkpoint gene, and 
altered BubR1 mRNA levels are associated with lymph node metastasis 
and chromosome instability. 
Methods: The expression of these four genes was identiﬁed in frozen 
resected tumors from 126 resected NSCLC p by real-time quantitative 
PCR. Gene expression was normalized using a-actin expression as 
internal reference. 
Results: Adenocarcinoma (adeno), 33 p; squamous cell carcinoma 
(SCC), 93 p. Stage: IA, 18 p; IB, 53 p; IIB, 33 p; IIIA, 22 p. Tumor 
transcript expression: RRM1, 2.10; Tdp1, 1.77; NFAT, 0.56; BubR1, 
16.40. Expression of RRM1, Tdp1 and BubR1 was higher in SCC than 
in adeno (P<0.001). Median time to relapse (TTR) was longer for p 
with low levels of RRM1 (P=0.11), Tdp1 (P=0.86), NFAT (P=0.29), 
or BubR1 (P=0.44). A signiﬁcant trend towards longer survival was 
observed in stage I p with low RRM1 P=0.06). In a multivariate Cox 
model, tumor size > 4 cm and stage III predicted shorter TTR and 
survival. 
Conclusion: Increased mRNA expression of these genes might be 
associated with shorter survival; this knowledge could be useful for 
customizing adjuvant chemotherapy.
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Background: Surgical resection for patients with stage IIIA (N2) non-
small cell lung cancer (NSCLC) results in disappointing 5-year survival 
rates (<10%). Most of these patients develop distant metastases, and 
this rationalizes the use of induction chemotherapy. There is ongoing 
discussion about the role of surgical resection (vs. radiotherapy) as 
local treatment modality after induction therapy. The aim of this retro-
spective analysis was to evaluate results of surgery and radiotherapy 
after neoadjuvant chemotherapy in the clinical setting. 
Methods: Patients with stage IIIA NSCLC treated with neoadjuvant 
chemotherapy from 1994 tot 2006 were identiﬁed from the cancer reg-
istration databases. During this period every treatment proposal or trial 
participation was discussed within a multidisciplinary thoracic oncol-
ogy committee. Response to induction therapy, deﬁnitive local therapy, 
recurrence of disease, and overall survival were reviewed. 
Results: Ninety-nine patients, 66 men and 33 women, were identiﬁed. 
The mean age was 61 (36-77), 40 tumors were left-sided. Neoadjuvant 
chemotherapy consisted of platin-based doublets/triplets. Clinical me-
diastinal downstaging was achieved in 32 patients. Thirty-nine patients 
underwent surgery, 19 lobectomies and 19 pneumonectomies were 
performed and one thoracotomy without resection. Forty-two patients 
received radiotherapy with radical intent. Nineteen patients received 
palliative treatment. 
Microscopic complete resection was achieved in 26 patients (69%). 
Histopathological response to induction therapy was complete (n=2), 
partial (n=23), or stable disease (n=13). The 2- and 5-year overall 
survival after surgery was 58% and 29% respectively, survival in lo-
bectomy patients being signiﬁcantly higher (p=0.03; ﬁg 1a+b). Surgical 
complications were infectious (n=4) or cardiovascular (n=7), mostly 
after pneumonectomy. The postoperative mortality was 3% (n=1, after 
pneumonectomy). 
Radiation doses actually delivered in patients with intended radical 
schemes ranged from 51 to 81 Gy, median dose given was 60 Gy. Grade 
3-4 radiation toxicity was seen in 10 patients. The 2- and 5-year overall 
survival after radiotherapy was 37% and 16% respectively (ﬁg 1a).
Conclusions: Radiotherapy is being regarded as the standard local 
treatment modality after neoadjuvant chemotherapy for stage IIIA 
NSCLC. Our retrospective data conﬁrm, that in selected patients com-
plete surgical resection (lobectomy) is also associated with long-term 
survival and cure.
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Background: Superior sulcus (Pancoast) tumors are preferably treated 
with neoadjuvant chemoradiotherapy and surgical resection. Induction 
chemoradiation increases the probability of a complete resection and 
local control, but is associated with an increased complication rate after 
surgery. Comorbidity, pulmonary reserve and response to induction 
treatment determine whether this demanding trimodality treatment can 
be advocated. Resections generally involve the upper lobe with con-
tiguous thoracic wall including apical ribs (and T1 plexus root /partial 
vertebra if necessary), but even more extensive resections have been 
performed in ﬁt patients. We evaluated the role of surgery as part of 
multimodality treatment in our institute.
Methods: From registration databases all patients with Pancoast 
tumors, referred to our institute between 1995 and 2006, were identi-
ﬁed. All patients without distant metastasis were selected for treatment 
with curative intent. The preferred treatment consisted of chemoradia-
tion (66 Gy radiotherapy in fractions of 2,75 Gy with daily cisplatinum 
6 mg/m2) followed by resection. Presenting symptoms, performance 
status, pulmonary function, clinical and pathological tumor stage, 
(response to) treatment, and survival were reviewed retrospectively. 
Survival analysis was performed using the Kaplan-Meier method.
Results: From 1995 to 2006, 85 patients with Pancoast tumors, 57 men 
and 28 women, were referred to our institute. The median follow-up 
was 15 months (2-123). Mean age was 57 years (32-82). After addi-
tional diagnostic staging, 25 patients had stage IIB (29%), 7 stage IIIA 
(8%), 32 stage IIIB (38%) and 21 stage IV (25%). Of those patients 
presenting with stage II or III disease, 22 underwent a resection after 
induction treatment. The 2- and 5-years overall survival was 70% and 
37%, respectively. 
All these resections were complete and local recurrences were not ob-
served. In 13 out of 22 patients a pathologic complete tumor response 
(pCR) was found after induction treatment. pCR was a signiﬁcant 
prognostic factor for survival (5 year survival of 50% vs. 17%). In most 
cases, pathologic response was not evident from radiologic imaging 
(restaging with CT or MRI). The morbidity of surgery after induction 
treatment was acceptable: 6 pneumonias, 1 tracheoesophageal ﬁstula, 
1 chylothorax, 1 complete atelectasis, 1 postoperative bleeding. There 
were no fatal toxicities or treatment-related mortalities. 
Forty-two patients were rejected for resection due to comorbidity/in-
operability (n=25), irresectability or insufﬁcient response on induction 
treatment. Nineteen of these patients received concurrent chemoradia-
tion (2- and 5-year survival 39% resp. 15%) and 23 patients were treated 
with radiotherapy, chemotherapy or both sequentially (2- and 5-year 
survival 18% resp. 5%). Local recurrence/progression occurred in 13 
out of 42 patients, six of these patients had distant metastases as well.
Conclusions: Surgical resection following induction chemoradiation 
is associated with excellent local control and acceptable long-term sur-
vival. Surgery however may not have additional value for patients with 
a pathologic complete response (pCR). Unfortunately, pCR could not 
be sufﬁciently recognized with conventional (CT/MRI) imaging. 
Expansion of indications for surgery following chemoradiation (com-
plex resections including vertebral cages etc) may be valuable in a few 
patients, although the number of isolated local recurrences in medically 
operable patients is small. 
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Background: Peritoneal micrometastasis is important staging factor in 
gastric and ovarian cancer. In NSCLCa, malignant pleural effusion is 
classiﬁed as T4. However, occult pleural micrometastasis is not clas-
siﬁed yet, because it is difﬁcult to detect using pleural lavage cytology 
during surgery due to its low sensitivity range of 4-14%. Touch print 
cytology is used to detect occult pleural micrometastasis easily with 
higher sensitivity. The impact of occult pleural micrometastasis is 
remained to be elucidated.
Methods: To detect pleural micrometastasis, we underwent touch print 
cytology test using glass slides and pleural lavage cytology test. Just 
after thoracotomy, touch print was carried with 2 pieces of glass slide 
from the visceral pleural surface of tumor mass of patients. Then, two 
pleural lavage cytology were collected at the times of pre-resection and 
post-resection (after distilled water irrigation) using each 1L of saline. 
The glass slides and lavages were examined for conﬁrming pleural 
micrometastasis of cancer cells. From June 1998 to March 2007, 311 
tumor masses of lung cancer patients have been subjected. Among 
them, 229 sets of cytology slides were reviewed completely.
Results: Touch print cytology was found to be positive in 68.9% 
(158/229), while pleural lavage cytology in 6.5% (15/229) of pre-resec-
tion and in 0.9% (2/229) of post-resection. All the positive pleural lavage 
cytology cases were included in the positive touch print cytology cases.
Conclusions: Occult pleural micrometastasis detected by using touch 
print cytology method is very common episode in NSCLCa patient 
during surgery.
